Simple jQuery Dropdowns

Browsing by Author Ricardo Pasquini

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)
1-Jul-2021Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)Hagop M. Kantarjian; Timothy P. Hughes; Richard A. Larson; Dong Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Carla Boquimpani; Ricardo Pasquini; Richard E. Clark; Viviane Dubruille; Ian W. Flinn; Slawomira Kyrcz-Krzemien; Ewa Medras; Maria Zanichelli; Israel Bendit; Silvia Cacciatore; Ksenia Titorenko; Paola Aimone; Giuseppe Saglio; Andreas Hochhaus; Siriraj Hospital; South Australian Health and Medical Research Institute; Section of Hematology Oncology, The University of Chicago; CHU de Nantes; Slaski Uniwersytet Medyczny w Katowicach; Charité – Universitätsmedizin Berlin; Royal Liverpool University Hospital; Universitätsklinikum Jena und Medizinische Fakultät; Sarah Cannon Research Institute; Universidade Federal do Parana; University of Texas MD Anderson Cancer Center; Università degli Studi di Torino; Novartis International AG; The University of Adelaide; Universidade de São Paulo; Wroclaw Medical University; Institut Bergonie; The Catholic University of Korea, College of Medicine; Novartis Pharma LLC; Oncoclínica Rio de Janeiro; Hemorio
15-Sep-2009Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)Hagop Kantarjian; Ricardo Pasquini; Vincent Lévy; Saengsuree Jootar; Jerzy Holowiecki; Nelson Hamerschlak; Timothy Hughes; Eric Bleickardt; David Dejardin; Jorge Cortes; Neil P. Shah; University of Texas MD Anderson Cancer Center; Hospital de Clínicas de Curitiba; Hopital Saint-Louis; Mahidol University; University Hospital-SPSKM; Hospital Israelita Albert Einstein; Institute of Medical and Veterinary Science Australia; Bristol-Myers Squibb; UCSF School of Medicine
1-Feb-2021Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M. Kantarjian; Timothy P. Hughes; Richard A. Larson; Dong Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Carla Boquimpani; Ricardo Pasquini; Richard E. Clark; Viviane Dubruille; Ian W. Flinn; Slawomira Kyrcz-Krzemien; Ewa Medras; Maria Zanichelli; Israel Bendit; Silvia Cacciatore; Ksenia Titorenko; Paola Aimone; Giuseppe Saglio; Andreas Hochhaus; Siriraj Hospital; South Australian Health and Medical Research Institute; Section of Hematology Oncology, The University of Chicago; CHU de Nantes; Slaski Uniwersytet Medyczny w Katowicach; Charité – Universitätsmedizin Berlin; Royal Liverpool University Hospital; Universitätsklinikum Jena und Medizinische Fakultät; Sarah Cannon Research Institute; Universidade Federal do Parana; University of Texas MD Anderson Cancer Center; Università degli Studi di Torino; Novartis International AG; The University of Adelaide; Universidade de São Paulo; Wroclaw Medical University; Institut Bergonie; The Catholic University of Korea, College of Medicine; Novartis Pharma LLC; Oncoclínica Rio de Janeiro; Hemorio
17-Jun-2010Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaGiuseppe Saglio; Dong Wook Kim; Surapol Issaragrisil; Philipp Le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E. Clark; Andreas Hochhaus; Timothy P. Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A. Larson; Hagop M. Kantarjian; Universita degli Studi di Torino; The Catholic University of Korea; Mahidol University; Charité – Universitätsmedizin Berlin; Institut Bergonie; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti; Universidade Federal do Parana; Royal Liverpool and Broadgreen University Hospitals NHS Trust; Universitatsklinikum Jena und Medizinische Fakultat; Royal Adelaide Hospital; Novartis International AG; Novartis Pharmaceuticals; University of Chicago; University of Texas MD Anderson Cancer Center